Schizophrenia

Although a warming planet is bad for human health overall, the prognosis for schizophrenia is particularly poor, researchers argue in a commentary.

The authors of an opinion piece in The Lancet Psychiatry make a case for paying more attention to the autistic features of schizophrenia.

The FDA has accepted the new drug application for the antipsychotic Bysanti and set a goal date for February 21, 2026.

Meanwhile, newly approved Cobenfy and the long-acting injectable antipsychotics may help with the long-standing problem of nonadherence to schizophrenia treatment.

KarXT — now with the brand name Cobenfy— is expected to be available in October with a list price of about $22,500 annually. The drug represents a new way to treat adults with schizophrenia.